Day One Biopharmaceuticals/$DAWN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Day One Biopharmaceuticals

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Ticker

$DAWN
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Brisbane, United States

Employees

181

ISIN

US23954D1090
Website
dayonebio.com

DAWN Metrics

BasicAdvanced
$672M
-
-$0.71
-1.30
-

What the Analysts think about DAWN

Analyst ratings (Buy, Hold, Sell) for Day One Biopharmaceuticals stock.

Bulls say / Bears say

Day One Biopharmaceuticals reported preliminary unaudited 2024 net product revenue of approximately $57.2 million for OJEMDA™ (tovorafenib), indicating strong market acceptance and potential for continued growth. (stocktitan.net)
The company secured approximately $175 million in an oversubscribed private placement, enhancing its financial position to support commercial capabilities, research and development, and potential strategic acquisitions. (investing.com)
Day One advanced its pipeline by progressing the Phase 3 FIREFLY-2 clinical trial and initiating the Phase 1a/b trial for DAY301, a PTK7-targeted ADC, demonstrating a commitment to expanding its oncology portfolio. (stocktitan.net)
Insider selling activity, including CEO Jeremy Bender's sale of approximately $149,524 worth of stock, may raise concerns about executive confidence in the company's future performance. (investing.com)
The company reported a net loss of $42.4 million in the first quarter, with increased research and development expenses, which could indicate ongoing financial challenges. (proactiveinvestors.com)
Day One's stock reached a new 12-month low, reflecting potential investor concerns about the company's valuation and future prospects. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

DAWN Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DAWN Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

DAWN News

AllArticlesVideos
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

GlobeNewsWire·4 weeks ago
Day One Reports First Quarter 2025 Financial Results and Corporate Progress

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

GlobeNewsWire·2 months ago
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DAWN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs